Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System

Little is known about tumor‐related prognostic factors, in particular specific chromosomal abnormalities, in young patients with multiple myeloma (MM). We therefore investigated the chromosomal pattern by interphase fluorescence in situ hybridization (chromosomes 13q14, 14q32‐translocations, chromos...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2007-03, Vol.78 (3), p.227-234
Main Authors: Sagaster, V., Kaufmann, H., Odelga, V., Ackermann, J., Gisslinger, H., Rabitsch, W., Zojer, N., Ludwig, H., Nösslinger, T., Zielinski, C., Drach, J.
Format: Article
Language:English
Subjects:
Adult
age
Age Distribution
Aged
Aged, 80 and over
Chromosome Aberrations
Humans
In Situ Hybridization, Fluorescence
International Staging System stage
Internationality
Interphase
Middle Aged
molecular cytogenetics
multiple myeloma
Multiple Myeloma - genetics
Multiple Myeloma - pathology
Neoplasm Staging - standards
Prognosis
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Little is known about tumor‐related prognostic factors, in particular specific chromosomal abnormalities, in young patients with multiple myeloma (MM). We therefore investigated the chromosomal pattern by interphase fluorescence in situ hybridization (chromosomes 13q14, 14q32‐translocations, chromosomes associated with hyperdiploidy) in 38 young patients with MM (age 70 yr). All chromosomal patterns were not significantly different between the three age cohorts. Similarly, standard MM parameters were equally distributed between these MM patient populations. However, survival by the International Staging System (ISS) for MM revealed marked differences between stage I/II (median survival not yet reached) and stage III (23.4 months; P 
ISSN:0902-4441
1600-0609
DOI:10.1111/j.1600-0609.2006.00807.x